SE312553B - - Google Patents
Info
- Publication number
- SE312553B SE312553B SE11025/62A SE1102562A SE312553B SE 312553 B SE312553 B SE 312553B SE 11025/62 A SE11025/62 A SE 11025/62A SE 1102562 A SE1102562 A SE 1102562A SE 312553 B SE312553 B SE 312553B
- Authority
- SE
- Sweden
- Prior art keywords
- group
- steroid
- formula
- ethylenic bond
- general formula
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
- A61K31/565—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids not substituted in position 17 beta by a carbon atom, e.g. estrane, estradiol
- A61K31/567—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids not substituted in position 17 beta by a carbon atom, e.g. estrane, estradiol substituted in position 17 alpha, e.g. mestranol, norethandrolone
-
- A—HUMAN NECESSITIES
- A43—FOOTWEAR
- A43B—CHARACTERISTIC FEATURES OF FOOTWEAR; PARTS OF FOOTWEAR
- A43B3/00—Footwear characterised by the shape or the use
- A43B3/12—Sandals; Strap guides thereon
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
- A61K31/565—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids not substituted in position 17 beta by a carbon atom, e.g. estrane, estradiol
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
- A61K31/565—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids not substituted in position 17 beta by a carbon atom, e.g. estrane, estradiol
- A61K31/568—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids not substituted in position 17 beta by a carbon atom, e.g. estrane, estradiol substituted in positions 10 and 13 by a chain having at least one carbon atom, e.g. androstanes, e.g. testosterone
- A61K31/569—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids not substituted in position 17 beta by a carbon atom, e.g. estrane, estradiol substituted in positions 10 and 13 by a chain having at least one carbon atom, e.g. androstanes, e.g. testosterone substituted in position 17 alpha, e.g. ethisterone
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
- A61K31/57—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids substituted in position 17 beta by a chain of two carbon atoms, e.g. pregnane or progesterone
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07J—STEROIDS
- C07J1/00—Normal steroids containing carbon, hydrogen, halogen or oxygen, not substituted in position 17 beta by a carbon atom, e.g. estrane, androstane
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07J—STEROIDS
- C07J63/00—Steroids in which the cyclopenta(a)hydrophenanthrene skeleton has been modified by expansion of only one ring by one or two atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07J—STEROIDS
- C07J7/00—Normal steroids containing carbon, hydrogen, halogen or oxygen substituted in position 17 beta by a chain of two carbon atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07J—STEROIDS
- C07J75/00—Processes for the preparation of steroids in general
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Organic Chemistry (AREA)
- Animal Behavior & Ethology (AREA)
- Pharmacology & Pharmacy (AREA)
- Epidemiology (AREA)
- Life Sciences & Earth Sciences (AREA)
- Medicinal Chemistry (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Steroid Compounds (AREA)
- Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Woven Fabrics (AREA)
- Phenolic Resins Or Amino Resins (AREA)
- Manufacturing Of Printed Wiring (AREA)
Abstract
Novel steroids of the general formula <FORM:1041279/C2/1> wherein R represents an alkyl group of at least 2 carbon atoms, R2 represents a substituted or unsubstituted alkyl, alkenyl or alkynyl group (a suitable substituent is methoxy) and ring A contains an ethylenic bond terminating at the 5-position, are prepared by hydrolysing a steroid of the general formula <FORM:1041279/C2/2> wherein X represents an acid-hydrolysable protected 3-oxo group, e.g. an alkoxy group such as the methoxy, ethoxy, methoxymethoxy and dihydroxypropyloxy, an alkylthio group such as alkylthio and benzylthio, an acyloxy group such as acetoxy, a dialkylamino group, an N-pyrrolidyl group, an alkylenedioxy group such as ethylenedioxy, an alkylenedithio group, or an alkylenethiooxy group, which is accompanied by an ethylenic bond terminating at the 5-position; by selectively reducing a steroid of the general formula <FORM:1041279/C2/3> wherein R represents an alkyl group and R1 has the above significance (a) by hydrogenation in solution in a non-protonic solvent using a palladium or Raney nickel catalyst to saturate the 14(15)-ethylenic bond, (b) by a carbonyl-reducing reagent such as sodium borohydride or lithium aluminium hydride, before or after the catalytic hydrogenation step to convert the carbonyl group to a hydroxymethylene group, (c) by the action of alkali metal in liquid ammonia after the catalytic hydrogenation and simultaneously with or after the carbonyl-reducing step, to saturate the 8(9)-ethylenic bond, and (d) by the action of alkali metal in liquid ammonia in the presence of a proton donor that is an alcohol having less than 6 carbon atoms, simultaneously with or after the saturation of the 8(9)-ethylene bond to form a steroid of the formula <FORM:1041279/C2/4> selectively oxidizing this compound to the corresponding 17-keto compound, and reacting this compound with an organo-metallic reagent containing the group R2; by ketalizing a corresponding steroid of the formula <FORM:1041279/C2/5> or <FORM:1041279/C2/6> wherein R represents an alkyl group, with an alkylene glycol to form a steroid of the formula <FORM:1041279/C2/7> wherein X represents an alkylenedioxy group and ring B has an ethylenic bond terminating at the 5-position, oxidizing this steroid to the corresponding 17-keto compound, treating the 17-keto compound with an organo-metal ethynylating agent to form the 17a -R2-17b -hydroxy-grouping and hydrolysing the ketal group at the 3-position to form a 4(5)-ethylenic steroid of the first formula above wherein R1 has the above significance and R2 represents an alkynyl group; by oxidizing a corresponding steroid diol of the formula <FORM:1041279/C2/8> having an ethylenic bond terminating at the 5-position, by isomerizing the corresponding steroids having an ethylenic bond in the 5(10)-position under basic or acidic conditions to form the corresponding 4(5)-unsaturated compounds; and by selectively reducing the steroids of the first general formula above wherein R2 is an unsaturated group to form corresponding steroids in which R2 is more saturated, for example by catalytic hydrogenation. The above formulae include all states of resolution except the resolved 13a -enantiomer. Pharmaceutical compositions which may be administered orally or by injection contain as the active ingredient a steroid of the first general formula above. The compositions may be used as anabolic agents.
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
GB37618/61A GB1041279A (en) | 1961-10-19 | 1961-10-19 | 13-alkyl steroid ketones |
Publications (1)
Publication Number | Publication Date |
---|---|
SE312553B true SE312553B (en) | 1969-07-21 |
Family
ID=10397775
Family Applications (6)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
SE11023/62A SE312551B (en) | 1961-10-19 | 1962-10-15 | |
SE11024/62A SE312552B (en) | 1961-10-19 | 1962-10-15 | |
SE11026/62A SE313809B (en) | 1961-10-19 | 1962-10-15 | |
SE01423/67A SE335526B (en) | 1961-10-19 | 1962-10-15 | |
SE11025/62A SE312553B (en) | 1961-10-19 | 1962-10-15 | |
SE05984/66A SE340619B (en) | 1961-10-19 | 1966-05-02 |
Family Applications Before (4)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
SE11023/62A SE312551B (en) | 1961-10-19 | 1962-10-15 | |
SE11024/62A SE312552B (en) | 1961-10-19 | 1962-10-15 | |
SE11026/62A SE313809B (en) | 1961-10-19 | 1962-10-15 | |
SE01423/67A SE335526B (en) | 1961-10-19 | 1962-10-15 |
Family Applications After (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
SE05984/66A SE340619B (en) | 1961-10-19 | 1966-05-02 |
Country Status (12)
Country | Link |
---|---|
AT (4) | AT264730B (en) |
CH (5) | CH432509A (en) |
CY (1) | CY429A (en) |
DE (4) | DE1618855B2 (en) |
DK (6) | DK113641B (en) |
ES (1) | ES281669A1 (en) |
FI (4) | FI41024B (en) |
FR (1) | FR2796M (en) |
GB (2) | GB1041278A (en) |
MY (1) | MY6800075A (en) |
NO (4) | NO122644B (en) |
SE (6) | SE312551B (en) |
Families Citing this family (3)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
DE2636404C2 (en) * | 1976-08-12 | 1983-12-08 | Schering AG, 1000 Berlin und 4709 Bergkamen | ?? 1?? 5? -17? -Ethynyl steroids of the estran series, processes for their preparation and pharmaceutical preparations containing them |
US8617597B2 (en) | 2006-07-06 | 2013-12-31 | Bayer Intellectual Property Gmbh | Pharmaceutical composition containing a tetrahydrofolic acid |
CN104926906B (en) * | 2015-06-04 | 2016-02-10 | 保定北瑞甾体生物有限公司 | A kind of preparation method of 17 Alpha-hydroxy Progesterone |
-
1961
- 1961-10-19 GB GB37617/61A patent/GB1041278A/en not_active Expired
- 1961-10-19 GB GB37618/61A patent/GB1041279A/en not_active Expired
-
1962
- 1962-10-15 SE SE11023/62A patent/SE312551B/xx unknown
- 1962-10-15 SE SE11024/62A patent/SE312552B/xx unknown
- 1962-10-15 SE SE11026/62A patent/SE313809B/xx unknown
- 1962-10-15 SE SE01423/67A patent/SE335526B/xx unknown
- 1962-10-15 SE SE11025/62A patent/SE312553B/xx unknown
- 1962-10-17 CH CH1562766A patent/CH432509A/en unknown
- 1962-10-17 CH CH1217162A patent/CH450407A/en unknown
- 1962-10-17 CH CH1562666A patent/CH450408A/en unknown
- 1962-10-17 CH CH1275267A patent/CH459195A/en unknown
- 1962-10-17 CH CH1562566A patent/CH455763A/en unknown
- 1962-10-17 DK DK448162AA patent/DK113641B/en unknown
- 1962-10-18 ES ES281669A patent/ES281669A1/en not_active Expired
- 1962-10-18 NO NO146141A patent/NO122644B/no unknown
- 1962-10-18 DK DK449762AA patent/DK115621B/en unknown
- 1962-10-18 DE DE19621618855 patent/DE1618855B2/en active Granted
- 1962-10-18 NO NO146140A patent/NO122643B/no unknown
- 1962-10-18 FI FI1876/62A patent/FI41024B/fi active
- 1962-10-18 DE DE1962S0082099 patent/DE1468604C2/en not_active Expired
- 1962-10-18 FI FI1879/62A patent/FI41027B/fi active
- 1962-10-18 NO NO146142A patent/NO122645B/no unknown
- 1962-10-18 DK DK449562AA patent/DK121228B/en unknown
- 1962-10-18 DE DE19621793608 patent/DE1793608B1/en active Pending
- 1962-10-18 AT AT822762A patent/AT264730B/en active
- 1962-10-18 NO NO146143A patent/NO122646B/no unknown
- 1962-10-18 DK DK449662AA patent/DK115549B/en unknown
- 1962-10-18 FI FI1877/62A patent/FI41025B/fi active
- 1962-10-18 FI FI1878/62A patent/FI41026B/fi active
- 1962-10-18 DE DE1962S0111837 patent/DE1617818B2/en active Granted
- 1962-10-19 AT AT825662A patent/AT256354B/en active
- 1962-10-19 AT AT825762A patent/AT256355B/en active
- 1962-10-19 AT AT825862A patent/AT256356B/en active
-
1963
- 1963-01-16 FR FR921556A patent/FR2796M/en not_active Expired
-
1966
- 1966-05-02 SE SE05984/66A patent/SE340619B/xx unknown
-
1968
- 1968-01-15 CY CY42968A patent/CY429A/en unknown
- 1968-12-31 MY MY196875A patent/MY6800075A/en unknown
-
1969
- 1969-04-24 DK DK227069AA patent/DK129652B/en unknown
-
1970
- 1970-06-30 DK DK339670AA patent/DK124753B/en unknown
Also Published As
Similar Documents
Publication | Publication Date | Title |
---|---|---|
GB1152226A (en) | Novel Gona-1,3,5(10)-Trienes, processes for their preparation, and compositions incorporating them | |
GB1163737A (en) | Improvements in or relating to 7-Dihalomethyl Steroids | |
GB1057117A (en) | Processes for preparing steroids compounds and the compounds when thus prepared | |
SE312551B (en) | ||
US3134771A (en) | 3-tetrahydropyranyl ethers of estra-1,3,5(10)-trienes | |
GB1141856A (en) | 19-nor-4,5-seco-steroids | |
GB928805A (en) | Steroid compounds | |
GB950899A (en) | Improvements in or relating to steroidal alkyl ethers | |
GB1010052A (en) | 13-alkyl steroids related to oestradiol | |
GB1010051A (en) | 13-alkyl steroids related to oestrone | |
GB1010053A (en) | 13-alkyl 5,10-ethylenic steroid 3-ketones and their enol ethers | |
ES338729A1 (en) | Medicinal compositions which contain 15,16beta-methylene steroids of the 19 nor-androstane series | |
GB927165A (en) | Improvements in or relating to steroids | |
GB991933A (en) | Tetracyclic aromatic diene compounds | |
Fahmy et al. | Metabolism of 19-hydroxy-C19-steroids by human corpus luteum | |
GB1024911A (en) | 8,9-ethylenic steroids and d-homo-steroids having an aromatic ring a | |
GB911428A (en) | Steroids | |
GB1041277A (en) | 13-alkyl steroids related to oestradiol | |
GB934574A (en) | Steroids | |
ES274471A1 (en) | Process for the preparation of 4-hydroxy-3-keto-í -steroids | |
GB999738A (en) | Therapeutic compositions containing estrones | |
GB985482A (en) | 2-methylene testosterone derivatives and methods for producing the same | |
GB1103204A (en) | 6,13 and 7,13-dialkylgonatetraene compounds | |
GB911740A (en) | Enolethers of 2- or 6-substituted í~-3-ketones of the androstane series | |
GB1006788A (en) | Improvements in or relating to the preparation of steroids |